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Abstract
Hydrogen sulfide (H2S), as a novel gaseous mediator, plays important roles in mammalian cardiovascular tissues. In the
present study, we investigated the cardioprotective effect of S-diclofenac (2-[(2,6-dichlorophenyl)amino] benzeneacetic acid
4-(3H-1,2,dithiol-3-thione-5-yl)phenyl ester), a novel H2S-releasing derivative of diclofenac, in a murine model of
doxorubicin-induced cardiomyopathy. After a single dose injection of doxorubicin (15 mg/kg, i.p.), male C57BL/6J mice
were given daily treatment of S-diclofenac (25 and 50 mmol/kg, i.p.), diclofenac (25 and 50 mmol/kg, i.p.), NaHS (50 mmol/kg,
i.p.), or same volume of vehicle. The cardioprotective effect of S-diclofenac was observed after 14 days. It showed that S-
diclofenac, but not diclofenac, dose-dependently inhibited the doxorubicin-induced downregulation of cardiac gap junction
proteins (connexin 43 and connexin 45) and thus reversed the remodeling of gap junctions in hearts. It also dose-
dependently suppressed doxorubicin-induced activation of JNK in hearts. Furthermore, S-diclofenac produced a dose-
dependent anti-inflammatory and anti-oxidative effect in this model. As a result, S-diclofenac significantly attenuated
doxorubicin-related cardiac injury and cardiac dysfunction, and improved the survival rate of mice with doxorubicin-
induced cardiomyopathy. These effects of S-diclofenac were mimicked in large part by NaHS. Therefore, we propose that
H2S released from S-diclofenac in vivo contributes to the protective effect in doxorubicin-induced cardiomyopathy. These
data also provide evidence for a critical role of H2S in the pathogenesis of doxorubicin-induced cardiomyopathy.
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Introduction
Doxorubicin is an anthracycline antibiotic widely used in the
treatment of a variety of human neoplastic diseases and solid
cancers, but its clinical application is hampered by progressive and
does-related cardiotoxicity including transient electrocardiograph-
ic abnormalities, cardiomyopathy and heart failure. The efficacy
of doxorubicin as a cytotoxic agent for the treatment of human
tumors has prompted a search to develop new agents to reduce its
cardiotoxicity [1–5].
Hydrogen sulfide, as a novel gaseous mediator, is generated
endogenously during cysteine metabolism in many types of
mammalian cells in the reaction catalysed by cystathionine b-
synthase (CBS) and cystathionine c-lyase (CSE) [6]. Although CBS
and CSE are widely distributed in tissues, CBS is the main H2S-
forming enzyme in central nervous system while CSE is the major
H2S-producing enzyme in cardiovascular system. It has become
clear that H2S fulfills a wide range of physiological and path-
ological functions in cardiovascular system [6]. Recent study has
shown that deficiencies of H2S synthesis may contribute to the
pathogenesis of doxorubicin-induced cardiomypathy and that
administration of NaHS, an H2S donor ameliorated doxorubicin-
related cardiac dysfunction via inhibiting oxidative stress injury
[7]. Therefore, application of H2S donors may be a promising
therapeutic strategy to prevent doxorubicin cardiotoxicity. How-
ever, NaHS is a short-lasting H2S donor, and it releases H2S
quickly, which may cause an acute alteration in hemodynamics. As
a result, further studies are needed to develop novel and potent
compounds that are capable of producing H2S slowly and stably.
S-diclofenac (2-[(2,6-dichlorophenyl) amino] benzene acetic
acid 4-(3H-1,2,dithiol-3-thione-5-yl) phenyl ester) is a novel
molecule comprising a H2S-releasing dithiol-thione moiety atta-
ched by an ester linkage to diclofenac. Unlike other H2S donors,
S-diclofenac releases H2S slowly both in vitro and in vivo over a
period of several hours [8,9]. Furthermore, S-diclofenac has
comparable or even improved anti-inflammatory property while
its gastrointestinal-damaging effect is considerably reduced as
compared with the parent drug [8,9]. These findings suggest that
S-diclofenac may be an attractive alternative to the available H2S
donors. On the other hand, one recent study has shown that S-
diclofenac could protect against ischemia–reperfusion injury in the
isolated rabbit heart [10]. The experiment, which indicates the
beneficial effect of S-diclofenac in ischemic heart diseases,
prompted us to investigate the possible protective effect of S-
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diclofenac might be able to block the progression of cardiomyop-
athy induced by doxorubicin, known for its late-onset acute and
chronic cardiotoxicity. To test that idea, in the present study, we
examined the cardioprotective effect of S-diclofenac in a murine
model of doxorubicin-induced cardiomyopathy and investigated
the specific mechanisms of its effect. Our data suggests that S-
diclofenac may attenuate the cardiotoxicity of doxorubicin by
reversing cardiac gap junction remodeling along with inhibiting
oxidative injury and inflammation in hearts.
Results
Deficiencies of H2S formation in doxorubicin-induced
cardiomyopathy
The model of dilated cardiomyopathy was induced in male 10-
week-old C57BL/6J mice by a single intraperitoneal injection of
doxorubicin at a dose of 15 mg/kg. The success of the model was
confirmed by decreased LV function and enlarged left ventricle of
the mice (by echocardiography). At necropsy, those mice exhibited
ascites and lobulated enlarged livers, indicative of liver congestion,
or foamy lungs indicative of lung edema, suggesting that they
undergo congestive heart failure.
Administration of doxorubicin resulted in a significant down-
regulation of CSE expression in heart. The mRNA and protein
levels of CSE were significantly decreased in hearts 14 days after
doxorubicin injection (n=6–8 in each group, P,0.01, Fig. 1A and
1B). As a result, a remarkable reduction in cardiac H2S
synthesizing activity and plasma level of H2S was observed in
doxorubicin injection group (n=6–8 in each group, P,0.01,
Figure 1C and 1D). Not surprisingly, consecutive administration
with S-diclofenac for 14 days dose-dependently diminished the
deficiencies of H2S formation induced by doxorubicin. As shown
in Figure 1C and 1D, S-diclofenac, but not diclofenac dose-
dependently abolished doxorubicin-induced reduction in cardiac
H2S synthesizing activity and plasma H2S concentration.
Alterations of gap junction proteins in doxorubicin-
induced cardiomyopathy
Gap junction channels are formed by the association of two
connexons composed of six protein subunits termed connexins
(Cxs) [11,12]. In mammalian hearts, gap junctions are principally
composed of three major connexin isoforms, Cx43, Cx40 and
Cx45. Therefore, we examined the cardiac expression levels of
Cx43, Cx45 and Cx40 in doxorubicin-induced cardiomyopathy.
As shown in Figure 2, the mRNA and proteins levels of Cx43 and
Cx45 in animal hearts were drastically downregulated 14 days
after doxorubicin injection (n=6–8 in each group, P,0.01).
However, no significant change in Cx40 mRNA and protein
expression was observed in animals injected with doxorubicin
(data not shown). It may be due to the fact that of most
mammalian species, Cx40 is abundant in gap junctions of atrial
myocytes but not of working ventricular myocytes [11,12].
Effect of S-diclofenac on doxorubicin-induced
downregulation of gap junction proteins
S-diclofenac at doses of 25 or 50 mmol/kg significantly
alleviated doxorubicin-induced downregulation of Cx43 and Cx
45, as compared to a mole for mole equivalent dose of diclofenac
(n=6–8 in each group, P,0.05, Figure 2A–D). S-diclofenac at a
higher dose was more potent than that at a lower dose to reverse
the suppression of Cxs expression in doxorubicin-induced
cardiomypathy. Furthermore, the effect of S-diclofenac on gap
junction proteins was in large part resembled by treatment with
NaHS, a conventional H2S donor. As shown in Figure 2E and 2F,
NaHS at a dose of 50 mmol/kg prominently provoked the mRNA
and protein expressions of Cx43 and Cx45 in doxorubicin-injected
mice (n=6–8 in each group, P,0.05).
Effect of S-diclofenac on doxorubicin-induced gap
junction remodeling
Doxorubicin-associated gap junction remodeling in mouse heart
was examined by transmission electron microscopy. Ultrastruc-
tural morphometry showed a significant reduction in gap junction
density (number of gap junctions per unit intercalated disk length)
14 days after doxorubicin injection (Figure 3A and Table 1).
Aggregate gap junction length per unit intercalated disk length was
also declined in doxorubicin group. Treatment with S-diclofenac
but not diclofenac led to a remarkable increase in both the number
and length of cardiomyocyte gap junctions (Figure 3A and
Table 1). A higher dose of S-diclofenac resulted in a more
impressive rise in gap junction number and length as compared to
a lower dose (Figure 3A and Table 1). Similarly, NaHS
significantly reversed the doxorubicin-induced gap junction
remodeling in heart (Figure 3B and Table 2).
Effect of S-diclofenac on doxorubicin-induced JNK
activation in hearts
To get more insights into the intracellular mechanism by which
S-diclofenac upregulated the cardiac expression of connexins in
doxorubicin-induced cardiomyopathy, further experiments were
performed to investigate the effect of S-diclofenac on JNK
activation, known to play a part in modulating the connexin
expression [13–16]. It was found that administration of doxoru-
bicin significantly activated the phosphorylation of JNK in hearts
(Figure 4, n=6 in each group). Treatment with S-diclofenac dose-
dependently inhibited doxorubicin-induced activation of JNK
(n=6 in each group, Figure 4A). NaHS at a dose of 50 mmol/kg
also markedly blocked the phosphorylation of JNK in doxorubi-
cin-injected mice (n=6 in each group, P,0.05, Figure 4B). In
contrast, diclofenac had no effect on JNK activation (Figure 4A).
In addition, we also examined the effect of H2S on ERK1/2 and
p38 MAPK pathways in this animal model. Both S-diclofenac and
NaHS failed to affect doxorubicin-evoked activation of ERK1/2
and p38 in hearts (data not shown).
Effect of S-diclofenac on doxorubicin-induced
inflammation and oxidative stress
Overproduction and/or ineffective scavenging of reactive
oxygen species (ROS) as well as inflammation play a crucial role
in the pathogenesis of doxorubicin-induced cardiomyopathy [2,3].
Therefore, we examined the effect of S-diclofenac on lipid
antioxidative mechanism (SOD and GSH activity), lipid peroxi-
dation activity (MDA content), and neutrophil infiltration (MPO
activtity) in hearts. As compared to a mole for mole equivalent
dose of diclofenac, S-diclofenac more potently alleviated doxoru-
bicin-induced inflammation in hearts as evidenced by a distinct
reduction in cardiac MPO activity (Table 3). Consistently, the
severity of oxidative stress caused by doxorubicin was also
significantly reduced by treatment with S-diclofenac. As shown
in Table 3, S-diclofenac, but not its parent drug markedly elevated
the cardiac activity of SOD and GSH-px and decreased the level
of MDA in hearts. The anti-inflammatory and anti-oxidative effect
of S-diclofenac was more potent at a higher dose. In addition,
treatment with NaHS also significantly inhibited doxorubicin-
associated inflammation and oxidative damage (Table 4).
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26441Figure 1. Alterations in endogenous H2S synthesis 14 days after doxorubicin injection (A–D) and effect of S-diclofenac on the
synthesis of H2S in doxorubicin-induced cardiomyopathy (C, D). Male 10-week-old C57BL/6J mice were randomly given doxorubicin (15 mg/
kg, i.p.) or same volume of saline. Treatment with S-diclofenac (25 and 50 mmol/kg, i.p.) or diclofenac (25 and 50 mmol/kg, i.p.) started 2 hours after
doxorubicin injection and continued every 24 hours. Fourteen days after doxorubicin injection, the expression level of CSE mRNA (A) and protein in
hearts (B), H2S synthesizing activity in hearts (C) and plasma H2S concentration (D) were measured as described in Materials and Methods. Results
shown are the mean 6 SEM (n=6–8 animals in each group). * P,0.01 vs saline group; { P,0.05 vs Dox+Diclo 25 mmol/kg group (animals treated
with doxorubicin+diclofenac 25 mmol/kg); { P,0.01 vs Dox+Diclo 50 mmol/kg group (animals treated with doxorubicin+diclofenac 50 mmol/kg).
doi:10.1371/journal.pone.0026441.g001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26441Figure 2. Effect of treatment with S-diclofenac (A–D) or NaHS (E, F) on Cx43 and Cx45 expression in hearts 14 days after
doxorubicin injection. Male 10-week-old C57BL/6J mice were randomly given doxorubicin (15 mg/kg, i.p.) or same volume of saline. Treatment
with S-diclofenac (25 and 50 mmol/kg, i.p.), diclofenac (25 and 50 mmol/kg, i.p.), NaHS (50 mmol/kg, i.p.) or vehicle started 2 hours after doxorubicin
injection and continued every 24 hours. Fourteen days after doxorubicin injection, hearts were harvested and examined by RT-PCR and Western blot
for the expression levels of Cx43 and Cx45. After analysis by densitometry, the data were expressed as ratios of Cxs to 18S or Cxs to b-actin (plotted as
percentage over saline group). Results shown are the mean 6 SEM (n=6–8 animals in each group). * P,0.05 vs saline group; { P,0.05 vs Dox+Diclo
25 mmol/kg group; { P,0.05 vs Dox+Diclo 50 mmol/kg group; ** P,0.05 vs. Dox+S-Dic 25 mmol/kg group (animals treated with doxorubicin and S-
diclofenac 25 mmol/kg); # P,0.05 vs. Dox group.
doi:10.1371/journal.pone.0026441.g002
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injury and cardiac dysfunction
Evidence of cardiac injury induced by intraperitoneal admin-
istration of doxorubicin was indicated by an obvious increase in
plasma levels of cardiac markers (LDH and CK) (Figure 5A), an
evident depression in left ventricular systolic function (LVEF and
LVFS) (Figure 5B) and an apparent dilation of left ventricles
(Figure 5C). Treatment with S-diclofenac but not diclofenac
protected mice against doxorubicin-induced cardiac injury. As
shown in figure 5A, plasma activities of LDH and CK were
significantly declined in mice treated with doxorubicin and S-
diclofenac as compared to those treated with doxorubicin and
diclofenac. The impairment of cardiac function caused by
doxorubicin was also attenuated by treatment with S-diclofenac,
as characterized by a significant elevation in LVEF and LVFS
(n=6–8 in each group, P,0.05, Figure 5B, 5D). S-diclofenac at a
Figure 3. Effect of treatment with S-diclofenac (A) or NaHS (B) on gap junction remodeling in hearts 14 days after doxorubicin
injection. (A) Representative transmission electron micrographs of gap junctions in hearts from saline group (A), Dox group (B), Dox+Diclo 25 mmol/
kg group (C), Dox+Diclo 50 mmol/kg group (D), Dox+S-Dic 25 mmol/kg group (E) and Dox+S-Dic 50 mmol/kg group (F) (n=5 animals in each group).
(B) Representative transmission electron micrographs of gap junctions in hearts from saline group (A), Dox group (B), Dox+NaHS 50 mmol/kg group
(C). Gap junctions are identified by arrows. Bars represent 0.2 mm (original magnification: 630000).
doi:10.1371/journal.pone.0026441.g003
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enlargement of left ventricle induced by doxorubicin (n=6–8 in
each group, P,0.05, Figure 5C, 5D). Similarly, NaHS signifi-
cantly decreased the plasma levels of LDH and CK, improved the
left ventricular dysfunction and attenuated left ventricle dilation in
doxorubicin-injected mice (n=6–8 in each group, Figure 5E, 5F,
5G).
In addition, administration with doxorubicin in mice resulted in
a high 14-day mortality rate. Treatment with S-diclofenac but not
diclofenac significantly improved the survival rate of the mice with
doxorubicin-induced cardiomyopathy. The 14-day survival rate of
the mice with doxorubicin-induced cardiomyopathy was signifi-
cantly elevated when treated with S-diclofenac at a dose of
50 mmol/kg (n=20 in each group, P,0.05, Figure 6).
Discussion
In the present study, we found that doxorubicin injection
downregulated the cardiac expression of CSE along with reduced
plasma H2S level and cardiac H2S synthesizing activity. Our
findings are in accord with earlier observations and reinforce the
significance of H2S insufficiency in the development of doxoru-
bicin-induced cardiotoxicity [7]. These results provide a solid basis
for the use of H2S donor drugs in the treatment of doxorubicin-
induced cardiotoxicity. We showed here that S-diclofenac, an
H2S-releasing diclofenac derivative, provided marked cardiopro-
tection in myocardial injury and cardiac dysfunction resulting
from doxorubicin injection. The cardioprotective effect of S-
diclofenac could be mimicked in large part by a mole for mole
equivalent dose of NaHS, a conventional H2S donor. Our findings
suggest that H2S release (from S-diclofenac) protects animals
against doxorubicin-associated cardiotoxicity and improves the
outcome of animals with doxorubicin-induced cardiomyopathy.
Although the pathogenesis of anthracycline cardiotoxicity has
been under intensive investigation for many years, the underlying
mechanisms are still not fully understood. Multiple explanations
have been proposed for the doxorubicin cardiotoxicity, e.g.
oxidative stress, inflammation, DNA damage, attenuation in
protein synthesis, alterations in cellular energetics and cardiomy-
ocyte apoptosis [1–5]. However, the present study is focused on
three aspects of the action of doxorubicin with respect to gap
junction remodeling, oxidative injury and inflammation.
Gap junction channels are responsible for direct cell-to-cell
communication and remodeling of gap junction organization is a
conspicuous feature of heart diseases. In the present study, we have
demonstrated for the first time that doxorubicin suppressed
cardiac expression of Cx43 and Cx45, resulting in loss of Cx43/
Cx45 junction channels and consequent spatial remodeling of gap
junctions, and thereby leading to progressive cardiac dysfunction
and left ventricular remodeling. Treatment with S-diclofenac, but
not diclofenac, not only remarkably upregulated the cardiac
expression of Cxs (Cx43 and Cx45) mRNA and proteins, but also
raised the density and length of gap junctions in doxorubicin-
induced cardiomyopathy. As a result, it considerably attenuated
heart injury and left ventricular enlargement, and improved left
ventricular ejection function and the survival rate of animals with
doxorubicin-induced cardiomyopathy. Moreover, the protective
effect of S-diclofenac could be mimicked by NaHS. Our data
straightforwardly demonstrate that H2S may exert its cardiopro-
tective effect in doxorubicin-induced cardiomyopathy via regulat-
ing connexin expression.
JNK is a crucial regulator of AP-1 activation which has been
shown to be necessary for activating Cx43 and Cx45 proximal
promoter [13,14]. Activation of JNK induced significant loss of
Cx43 expression and decreased the numbers of gap junctions in
cultured cardiomyocytes and transgenic mouse ventricular myo-
cardium [15,16]. Therefore, we further examined the relevance of
JNK pathway to the protective effect of S-diclofenac. We found
that doxorubicin induced an obvious activation of JNK in hearts,
suggesting that doxorubicin-induced downregulation of Cx43 and
Cx45 is possibly mediated by JNK pathway. Treatment with S-
diclofenac or NaHS significantly inhibited the phosphorylation of
JNK in hearts from doxorubicin-injected mice. Hence, it seems
reasonable to assume that S-diclofenac derived H2S may abolish
doxorubicin-associated downregulation of Cxs by inhibiting the
cardiac activity of JNK. However, the precise points of interaction
Table 1. Effect of S-diclofenac on gap junction remodeling induced by doxorubicin.
Number of gap junctions Gap junction length
(per 100 mm ID length) (mm per 100 mm ID length)
Saline 19.3364.63 17.6764.40
Dox 4.5762.69* 5.5062.35*
Dox+Diclo 25 mmol/kg 4.8562.79* 5.9662.16*
Dox+Diclo 50 mmol/kg 5.1461.57* 6.2361.96*
Dox+S-Dic 25 mmol/kg 9.8562.41{ 10.8162.04{
Dox+S-Dic 50 mmol/kg 14.5762.63{** 15.3562.83{**
*P,0.01 vs saline group;
{P,0.05 vs mice treated with doxorubicin+diclofenac 25 mmol/kg;
{P,0.05 vs mice treated with doxorubicin+diclofenac 50 mmol/kg;
**P,0.05 vs mice treated with doxorubicin+S-diclofenac 25 mmol/kg; ID: intercalated disc.
doi:10.1371/journal.pone.0026441.t001
Table 2. Effect of NaHS on gap junction remodeling induced
by doxorubicin.
Number of gap junctions Gap junction length
(per 100 mm ID length) (mm per 100 mm ID length)
saline 18.1767.41 15.5763.65
Dox 5.2962.87* 6.7161.53*
Dox+NaHS 12.1462.97** 10.2662.06**
*P,0.05 vs saline group;
**P,0.05 vs mice treated doxorubicin.
doi:10.1371/journal.pone.0026441.t002
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26441Figure 4. Effect of treatment with S-diclofenac (A) or NaHS (B) on JNK activation in hearts 14 days after doxorubicin injection. Male
10-week-old C57BL/6J mice were randomly given doxorubicin (15 mg/kg, i.p.) or same volume of saline. Treatment with S-diclofenac (25 and
50 mmol/kg, i.p.), diclofenac (25 and 50 mmol/kg, i.p.) or NaHS (50 mmol/kg, i.p.) started 2 hours after doxorubicin injection and continued every
24 hours. Fourteen days after doxorubicin injection, hearts were harvested and examined by Western blot for total and phospho-JNK. After analysis
by densitometry, the data were expressed as ratios of phosphorylated protein to total protein (plotted as fold increase over saline group, n=6
animals in each group). * P,0.05 vs saline group; { P,0.05 vs Dox+Diclo 25 mmol/kg group; { P,0.05 vs Dox+Diclo 50 mmol/kg group; ** P,0.05 vs.
Dox+S-Dic 25 mmol/kg group; # P,0.05 vs. Dox group.
doi:10.1371/journal.pone.0026441.g004
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the present in vivo experiments and further work is needed most
likely in an isolated cardiomyocyte system to probe the exact
mechanisms involved. In addition to transcription, post-transla-
tional modifications such as phosphorylation are also important for
connexin trafficking and assembly at gap junctions [17,18]. It has
been shown that phosphorylation of connexins regulates many
aspects of the gap junction life cycle including assembly, gating,
internalization, and degradation [17]. Whether H2S could alter
the biological functions of gap junctions via modulating the
phosphorylation of Cxs in doxorubicin-induced cardiotoxicity will
be the subject of our future study.
Moreover, latest studies have proposed that doxorubicin-induced
cardiomyopathy is primarily a stem cell disease [19,20]. Cardio-
toxicity of the anthracycline is not restricted to cardiomyocytes but
affects resident cardiac progenitor cells (CPCs) even more
dramatically. Anthracycline not only inhibited the growth and
survival of CPCs but also impaired global gene expression of CPCs.
Reduction in the number of CPCs and defects in progenitor cell
function finally lead to the development of cardiac myopathy or
result in an adult heart that is more susceptible to stress. These
findings offer an original possibility that H2So rH 2S donor drugs
may attenuate the loss of CPCs or the impairment of CPC capacity
induced by doxorubicin, thus enhancing the myocardial regener-
ation and restoring the structural integrity of cardiomyopathic
heart. Interestingly, in the present study, we did find that S-
diclofenac or NaHS significantly elevated the expression levels of
junctional proteins (Cx43 and Cx45) and partially reversed the
remodeling of gap junctions in hearts. Therefore, it is meaningful to
further investigate the type of cardiac cells affected by H2S and the
underlying molecular mechanisms in the future study.
On the other hand, we found that doxorubicin suppressed the
activities of antioxidant enzymes and caused overproduction and/
or ineffective scavenging of ROS in hearts while S-diclofenac
prevented these pathological processes. Similar antioxidative
properties of H2So rH 2S donor drugs were observed previously
in neurons, vascular smooth muscle cells and neutrophils. H2S
may suppress ROS generation and ameliorate oxidative insult by
different mechanisms: 1) H2S may increase the activity of diverse
antioxidant enzymes; 2) H2S may increase the levels of glutathione
participating in regulating oxidative stress; 3) H2S, as a highly
reactive molecule may easily react with ROS and/or reactive
nitrogen species (NOS); 4) H2S may open ATP-dependent K
+ and
Cl
2 channels [21–23]. Additionally, S-diclofenac has been shown
to exhibit greater anti-inflammatory activity (compared to
diclofenac) in the present study. A superior anti-inflammatory
effect of S-diclofenac (compared to diclofenac) was also observed
in animal models of hindpaw edema, acute panreatitis as well as
endotoxemia [8,24,25]. The additional anti-inflammatory activity
of S-diclofenac may be at least partially due to release of H2S. S-
diclofenac derived H2S inhibited inflammatory response by
downregulating the transcription of inflammation related genes
via NF-kB pathway [8]. However, it is to be noted that H2S has
been shown to play complex but poorly understood roles in
inflammation with evidence for proinflammatory as well as anti-
inflammatory properties. It was reported that H2S provoked the
inflammatory response in sepsis, acute pancreatitis and endotox-
emia [26,27,28]. In contrast, H2S inhibited leukocyte migration in
animal models of paw edema and nonsteroidal anti-inflammatory
drugs (NSAIDs)-induced gastric injury [29,30]. Although the role
of H2S in inflammation remains controversial, it raises the
possibility that H2S may act as a double-edged sword in
Table 3. Effect of S-diclofenac on inflammatory response and oxidative stress in heart.
MPO activity MDA SOD GSH-Px
(Fold increase over control) (nmol/g protein) (U/mg protein) (U/mg protein)
Saline 160.20 73.9963.64 137.46610.38 34.0962.68
Dox 2.8960.69* 161.0565.32* 70.5166.94* 16.4161.18*
Dox+Diclo 25 mmol/kg 2.3160.35*# 158.2367.25* 68.4665.97* 15.4961.24*
Dox+Diclo 50 mmol/kg 2.0860.20*# 163.7769.83* 65.9464.38* 14.7161.54*
Dox+S-Dic 25 mmol/kg 1.7060.33{ 127.4366.77{ 97.8563.41{ 22.9861.23{
Dox+S-Dic 50 mmol/kg 1.1560.24{** 90.90610.28{** 124.6367.09{** 30.2961.98{**
*P,0.01 vs saline group;
#P,0.05 vs mice treated with doxorubicin;
{P,0.05 vs mice treated with doxorubicin+diclofenac 25 mmol/kg;
{P,0.05 vs mice treated with doxorubicin+diclofenac 50 mmol/kg;
**P,0.05 vs mice treated with doxorubicin+S-diclofenac 25 mmol/kg.
doi:10.1371/journal.pone.0026441.t003
Table 4. Effect of NaHS on inflammatory response and oxidative stress in heart.
MPO activity MDA SOD GSH-Px
(Fold increase over control) (nmol/g protein) (U/mg protein) (U/mg protein)
saline 160.16 82.2664.36 147.45611.16 36.1161.89
Dox 2.4660.46* 134.0166.23* 78.2664.89* 13.0861.04*
Dox+NaHS 1.4660.27** 102.3669.55** 109.8364.65** 19.0861.81**
*P,0.05 vs saline group;
**P,0.05 vs mice treated doxorubicin.
doi:10.1371/journal.pone.0026441.t004
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26441Figure 5. Effect of treatment with S-diclofenac or NaHS on plasma levels of cardiac marker enzymes and cardiac function 14 days
after doxorubicin injection. Male 10-week-old C57BL/6J mice were randomly given doxorubicin (15 mg/kg, i.p.) or same volume of saline.
Treatment with S-diclofenac (25 and 50 mmol/kg, i.p.). diclofenac (25 and 50 mmol/kg, i.p.) or NaHS (50 mmol/kg, i.p.) started 2 hours after doxorubicin
injection and continued every 24 hours. Fourteen days after doxorubicin injection, plasma activities of CK and LDH (A, E), left ventricular systolic
function (B, F) as well as left ventricular dimensions (C, G) were measured as described in Materials and Methods (n=6–8 animals in each group). (D)
Representative M-mode echocardiographs from saline group (A), Dox group (B), Dox+Diclo 25 mmol/kg group (C), Dox+Diclo 50 mmol/kg group (D),
Dox+S-Dic 25 mmol/kg group (E) and Dox+S-Dic 50 mmol/kg group (F). * P,0.05 vs saline group; { P,0.05 vs Dox+Diclo 25 mmol/kg group; { P,0.05
vs Dox+Diclo 50 mmol/kg group; ** P,0.05 vs. Dox+S-Dic 25 mmol/kg group; # P,0.05 vs. Dox group.
doi:10.1371/journal.pone.0026441.g005
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mediator to at physiological concentration, but may contribute to
inflammation in an already inflamed area when overproduced.
In addition, S-diclofenac has distinct advantages over NaHS in
the treatment of doxorubicin-induced cardiomyopathy, although
both of them protected animals against doxorubicin-induced
myocardial injury. Firstly, H2S release from S-diclofenac is a slow
process probably mediated by plasma/tissue esterase, which split
the ester linkage of the parent compound to form ADT-OH. This
molecule thereafter releases H2S either by spontaneous chemical
degradation or by an as yet unidentified metabolic process. Hence,
S-diclofenac has been considered as a slow-releasing H2S donor.
Administration of S-diclofenac had minimal effect on blood
pressure [8]. In stark contrast, NaHS breaks down rapidly in
aqueous solution to yield Na
+ and HS
2, the latter then reacting
with H
+ to form H2S. Administration of NaHS caused a
pronounced but transient decrease in blood pressure [28,31].
Secondly, recent studies have demonstrated that S-diclofenac may
have a potential usefulness in cancer treatment [32]. S-diclofenac
has been found to inhibit the activity and expression of carcinogen
activating enzymes and may serve as effective chemoprevention
agents by balance the equation of carcinogen activation and
detoxification mechanisms [32]. Therefore, we propose that in
comparison to NaHS, S-diclofenac may be a better option to
prevent cardiac complications from anthracyclines in cancer
patients undergoing chemotherapy with doxorubicin.
In summary, S-diclofenac attenuated doxorubicin-induced
cardiac gap junction remodeling, oxidative stress and inflamma-
tory response. The pharmacological profiles of S-diclofenanc, i.e.
cardioprotective activity, suggest that this compound might
constitute a potentially new therapeutic option to prevent
doxorubicin-induced cardiotoxicity. However, further clinical
studies will have to verify if this concept is valid in patients as
well, and whether or not S-diclofenac treatment counteracts with
the oncological effect of doxorubicin.
Materials and Methods
Chemicals
Doxorubicin was obtained from Wanle Pharmaceutical Indus-
try (Shenzhen, China) as a 10 mg/bottle lyophilized powder. The
malondialdehyde (MDA, a marker of lipid peroxidation and free
radical activity), glutathione peroxidase (GSH-Px) and superoxide
dismutase (SOD) assay kits were purchased from Nanjing
Jiancheng Bio-engineering Institute (Nanjing, China). S-diclofenac
was obtained from CTG Pharma, Milan, Italy.
Animals and experimental protocols
The study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Shanghai JiaoTong University School
of Medicine. The protocol was approved by the Committee on
the Ethics of Animal Experiments of the Shanghai JiaoTong
University School of Medicine (Permit Number: [2011]-22).
Male 10-week-old C57BL/6J mice were randomly assigned to
receive doxorubicin (15 mg/kg, i.p.) or same volume of saline
(i.p.). Two hours after doxorubicin injection, diclofenac (25 and
50 mmol/kg, i.p.), S-diclofenac (25 and 50 mmol/kg, i.p.), NaHS
(50 mmol/kg, i.p.) or same volume of vehicle (0.5% w/v
carboxymethylcellulose or saline, i.p.) were administered daily
for 14 consecutive days. The dosage of S-diclofenac was
determined based on previous study [8]. Fourteen days after
doxorubicin injection, animals were sacrificed by an i.p. injection
of a lethal dose of pentobarbitone (90 mg/kg). Samples of hearts
and plasma were harvested and stored at 280uC for subsequent
measurement.
Figure 6. Effect of treatment with S-diclofenac on survival rate of mice subjected to doxorubicin injection. Male 10-week-old C57BL/6J
mice were randomly given doxorubicin (15 mg/kg, i.p.) or same volume of saline. Treatment with S-diclofenac (25 and 50 mmol/kg, i.p.) or diclofenac
(25 and 50 mmol/kg, i.p.) started 2 hours after doxorubicin injection and continued every 24 hours. Their survival rate was monitored for 14 days
(n=20 animals in each group). The 14-day survival rate in Dox+S-Dic 50 mmol/kg group were significantly higher than that in Dox+Diclo 50 mmol/kg
group (P,0.05).
doi:10.1371/journal.pone.0026441.g006
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Aliquots (120 ml) of plasma were mixed with distilled water
(100 ml), trichloroacetic acid (10% w/v, 120 ml), zinc acetate (1%
w/v, 60 ml), N, N-dimethyl-p-phenylenediamine sulfate (20 mM;
40 ml) in 7.2 M HCl and FeCl3 (30 mM; 40 ml) in 1.2 M HCl. The
absorbance of the resulting solution (670 nm) was measured
10 min thereafter by spectrophotometry (Tecan Systems Inc.).
H2S was calculated against a calibration curve of sodium
hydrosulfide (NaHS; 3.125–100 mM). Results were showed plasma
H2S concentration in mM.
Assay of H2S synthesizing activity
H2S synthesizing activity in heart homogenates was measured
essentially as described elsewhere [26]. Briefly, the assay mixture
contained 100 mM potassium phosphate buffer (pH 7.4), L-
cysteine (20 ml, 20 mM), pyridoxyal 59-phosphate (20 ml, 2 mM),
saline (30 ml) and 4.5% w/v tissue homogenate (430 ml). The
reaction was performed in tightly sealed micro centrifuge tubes
and initiated by transferring the tubes from ice to a water bath at
37uC. After incubation for 30 min, 1% w/v zinc acetate (250 ml)
was added to trap evolved H2S followed by 10% v/v trichlor-
oacetic acid (250 ml) to denature the protein and stop the reaction.
Subsequently, N, N-dimethyl-p-phenylenediamine sulfate (20 mM;
133 ml) in 7.2 M HCl was added, immediately followed by FeCl3
(30 mM; 133 ml) in 1.2 M HCl. The absorbance of the resulting
solution at 670 nm was measured by spectrophotometry (Tecan
Systems Inc). The H2S concentration was calculated against a
calibration curve of NaHS. Results were then corrected for the
DNA content of the tissue sample [33] and were expressed as
nmoles H2S formed/mg DNA.
RT-PCR analysis
Total RNA from heart was extracted with Trizol H reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
protocol. The concentration of isolated nuclei acids was
determined spectrophotometrically by measuring the absorbance
at 260 nm and the integrity was verified by ethidium bromide
staining of 18S and 28S rRNA bands on a denaturing agarose gel.
All samples were thereafter stored at 280uC until required. 1 mg
RNA was reversely transcribed using iScript
TM cDNA Synthesis
Kit (Biorad, Hercules, CA, USA) at 25uC for 5 minutes, 42uC for
30 minutes, followed by 85uC for 5 minutes. The cDNA was used
as a template for PCR amplification by iQ
TM Supermix (Biorad,
Hercules, CA, USA). The primer sequences for detection of CSE,
Cx43, Cx45, Cx40 and 18S, optimal annealing temperature,
optimal cycles and product sizes were as shown in table 5. PCR
amplification was carried out in MyCycler
TM (Biorad, Hercules,
CA, USA). The reaction mixture was first subjected to 95uC for
3 minutes, followed by an optimal cycle of amplifications,
consisting of 95uC for 50 s, optimal annealing temperature for
45 s and 72uC for 1 minute. PCR products were analyzed on
1.5% w/v agarose gels containing 0.5 mg/ml ethidium bromide.
Western immunoblot
Left ventricles were homogenized at 4uC in radioimmunopre-
cipitation assay lysis buffer supplemented with protease inhibitor
cocktail (Roche, Switzerland). The tissue homogenates were
centrifuged at 14,000 g for 10 min at 4uC. Protein concentration
in the soluble fraction was determined by Bradford method.
Protein samples (100 mg) were separated by 12% SDS-polyacryl-
amide gel and then transferred onto polyvinylidene difluoride
membranes. Membranes were then washed, blocked, and probed
overnight at 4uC with rabbit anti-Cx43 (1:1000, Chemicon, USA),
Cx45 (1:1000, Chemicon, USA), Cx40 (1:1000, Chemicon, USA),
JNK (1:2000, Cell Signaling Technology, USA), phospho-JNK
(1:1000, Cell Signaling Technology, USA), b-actin (1:2000, Santa
Cruz Biotechnology, USA) and mouse monoclonal anti-CSE
antibody (1:1000, Abnova, Taiwan) respectively, followed by
secondary antibody for 2 h with a 1:2000 dilution of HRP-
conjugated, goat anti-rabbit IgG or goat anti-mouse IgG (Santa
Cruz Biotechnology, USA). Membranes were washed and then
incubated in SuperSignal
TM West Pico chemiluminescent sub-
strate (Pierce, USA) before exposure to X-ray films (Pierce, USA).
The intensity of bands was quantified using LabWorks
TM Image
Analysis software (UVP).
Myeloperoxidase estimation (MPO)
Heart samples were thawed, homogenized in 20 mM phosphate
buffer (pH 7.4), centrifuged (13,0006 g, 10 min, 4uC) and the
resulting pellets were resuspended in 50 mM phosphate buffer
(pH 6.0) containing 0.5% w/v hexadecyltrimethylammonium
bromide (Sigma). The suspension was subjected to four cycles of
freezing and thawing and further disrupted by sonication
(40 seconds). The samples were then centrifuged (13,0006 g,
5 min, 4uC) and the supernatants were used for the MPO assay.
The reaction mixture consisted of the supernatant (50 ml), 1.6 mM
tetramethylbenzidine (Sigma), 80 mM sodium phosphate buffer
(pH 5.4), and 0.3 mM hydrogen peroxide (reagent volume: 50 ml).
Table 5. PCR primer sequences, optimal conditions and product sizes.
Gene Primer sequence Optimal conditions Size
CSE Forward: 59-GACCTCAATAGTCGGCTTCGTTTC-39 34 cycles 618 bp
Reverse: 59-CAGTTCTGCGTATGCTCCGTAATG-39 Annealing: 61uC
Cx43 Forward: 59-TACCACGCCACCACCGGCCCA-39 30 cycles 293 bp
Reverse: 59-GGCATTTTGGCTGTCGTCAGGGAA-39 Annealing: 60uC
Cx45 Forward: 59-CCCCTGATTTGCTACTAA-39 35 cycles 250 bp
Reverse: 59-AATGCTAAGATTGCCTACA-39 Annealing: 52uC
Cx40 Forward: 59-ATGGGTGACTGGAGCTTCC-39 36 cycles 255 bp
Reverse: 59-CACAAAGATGATCTGCAGTACCC-39 Annealing: 52uC
18S Forward: 59-CCATCCAATCGGTAGTAGCG-39 22 cycles 150 bp
Reverse: 59-GTAACCCGTTGAACCCCATT-39 Annealing: 59uC
doi:10.1371/journal.pone.0026441.t005
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terminated with 50 ml of 0.18 M H2SO4 and the absorbance was
measured at 405 nm. This absorbance was then corrected for the
DNA content of the tissue sample and the results were expressed as
enzyme activity.
Assay of MDA content, activity of SOD and GSH-Px in
heart
Cardiac tissue samples (25 mg) were homogenized in 0.5 ml of
PBS at 4uC with a homogenizer. Homogenates were then
centrifuged at 1500 rpm for 30 min and the supernatants were
collected. MDA content as well as SOD and GSH-px activity in
supernatants were evaluated with MDA, SOD and GSH-Px assay
kits according to the manufacturer’s protocol.
Assay of creatine kinase (CK) and lactate dehydrogenase
(LDH) enzyme activities
Plasma CK and LDH enzyme activities were measured using an
autoanalyzer (Model 7020, Hitachi Medico, Japan).
Transmission electron microscopy
In order to analyze gap junction remodeling, left ventricular
tissues were immersion-fixed in phosphate-buffered 2.5% glutar-
aldeyde (pH 7.4), post-fixed with 1% osmium tetroxide, dehy-
drated through a graded ethanol series and embedded in Epon
medium. Ultrathin sections were observed by electron microscopy
(JEM1230; JEOL Transmission Electron Microscope, Tokyo,
Japan). Five hearts from each group were examined. Ten pictures
were taken from each heart and analyzed morphometrically using
methods described previously [34,35]. At a magnification of
30,000, every intercalated disk profile identified within each test
area was rephotographed and the total number and length of gap
junctions and the total length of intercalated disks were measured.
Gap junction number and length was calculated per unit
intercalated disk length as previously described [34,35].
Echocardiography
Mice were lightly anesthetized with isoflurane gas. AUBM
system (Vevo 770, Visualsonics, Toronto, Canada) equipped with
a 7.5-MHz imaging transducer was used for all the examinations.
The transducer was placed in gentle contact with the mid-
precordial area through a transmission medium. Left ventricular
ejection fraction (LVEF), left ventricular fractional shortening
(LVFS), left ventricular internal dimensions at the end of diastole
(LVEDD) and at the end of systole (LVESD) were measured
digitally on the M-mode tracing.
Statistics
The data were expressed as mean 6 SEM. The significance of
differences among groups was evaluated by analysis of variance
(ANOVA) with post-hoc Tukey’s test when comparing three or
more groups. The significance of differences between two groups
was evaluated by T test. The overall survival analysis for lethal
injury was described by Kaplan-Meier plots. The difference of
mortality among groups was tested by log rank test. A P,0.05 was
regarded as statistically significant.
Acknowledgments
We thank Dr. Huang Lin and Dr. Jia Jianguo for their help with the animal
experiments.
Author Contributions
Conceived and designed the experiments: HZ CW. Performed the
experiments: HZ AZ CG. Analyzed the data: CS YZ QL. Contributed
reagents/materials/analysis tools: AS. Wrote the paper: HZ.
References
1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines:
molecular advances and pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev 56: 185–229.
2. Hrdina R, Gersl V, Klimtova ´ I, Simu ˚nek T, Macha ´ckova ´ J, et al. (2000)
Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove) 43: 75–82.
3. Jones RL, Swanton C, Ewer MS (2006) Anthracycline cardiotoxicity. Expert
Opin Drug Saf 5: 791–809.
4. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE (2005)
Protecting against anthracycline-induced myocardial damage: a review of the
most promising strategies. Br J Haematol 131: 561–578.
5. Singal PK, Iliskovic N, Li T, Kumar D (1997) Adriamycin cardiomyopathy:
pathophysiology and prevention. FASEB J 11: 931–936.
6. Łowicka E, Bełtowski J (2007) Hydrogen sulfide (H2S) – the third gas of interest
for pharmacologists. Pharmacol Rep 59: 4–24.
7. Su YW, Liang C, Jin HF, Tang XY, Han W, et al. (2009) Hydrogen sulfide
regulates cardiac function and structure in adriamycin-induced cardiomyopathy.
Circ J 73: 741–749.
8. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, et al. (2007) Anti-
inflammatory and gastrointestinal effects of a novel H2S-releasing diclofenac
agent. Free Radical Biol Med 42: 706–719.
9. Wallace JL, Caliendo G, Santagada V, Cirino G, Fiorucci S (2007)
Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-
releasing diclofenac derivative in the rat. Gastroenterology 132: 261–271.
10. Rossoni G, Sparatore A, Tazzari V, Manfredi B, Del Soldato P, et al. (2008) The
hydrogen sulphide-releasing derivative of diclofenac protects against ischaemia–
reperfusion injury in the isolated rabbit heart. Br J Pharmacol 153: 100–109.
11. Kumar NM, Gilula NB (1996) The gap junction communication channel. Cell
84: 381–388.
12. Desplantez T, Dupont E, Severs NJ, Weingart R (2007) Gap junction channels
and cardiac impulse propagation. J Membr Biol 218: 13–28.
13. Geimonen E, Jiang W, Ali M, Fishman GI, Garfield RE, et al. (1996) Activation
of protein kinase C in human uterine smooth muscle induces connexin-43 gene
transcription through an AP-1 site in the promoter sequence. J Biol Chem 271:
23667–23674.
14. Baldridge D, Lernando F, Shin CS, Stains J, Civitelli R (2001) Sequence and
structure of the mouse connexin45 gene. Bioscience Rep 21: 683–689.
15. Petrich BG, Gong X, Lerner DL, Wang X, Brown JH, et al. (2002) c-Jun N-
terminal kinase activation mediates downregulation of connexin43 in cardio-
myocytes. Circ Res 91: 640–647.
16. Teunissen BE, Bierhuizen MF (2004) Transcriptional control of myocardial
connexins. Cardiovasc Res 62: 246–255.
17. Beardslee MA, Lerner DL, Tadros PN, Laing JG, Beyer EC, et al. (2000)
Dephosphorylation and intracellular redistribution of ventricular connexin 43
during electrical uncoupling induced by ischemia. Circ Res 87: 656–662.
18. Schulz R, Gres P, Skyschally A, Duschin A, Belosjorow S, et al. (2003) Ischemic
preconditioning preserves connexin 43 phosphorylation during sustained
ischemia in pig hearts in vivo. FASEB J 17: 1355–1357.
19. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, et al. (2010)
Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell
pool and is rescued by restoration of progenitor cell function. Circulation 121:
276–292.
20. Huang C, Zhang X, Ramil JM, Rikka S, Kim L, et al. (2010) Juvenile exposure
to anthracyclines impairs cardiac progenitor cell function and vascularization
resulting in greater susceptibility to stress-ionduced myocardial injury in adult
mice. Circulation 121: 675–683.
21. Kimura Y, Kimura H (2004) Hydrogen sulfide protects neurons from oxidative
stress. FASEB J 18: 1165–1167.
22. Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS, et al. (2004) The
novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite ‘scaven-
ger’? J Neurochem 90: 765–768.
23. Whiteman M, Li L, Kostetski I, Chu SH, Siau JL, et al. (2006) Evidence for the
formation of a novel nitrosothiol from the gaseous mediators nitric oxide and
hydrogen sulphide. Biochem Biophys Res Commun 343: 303–310.
24. Bhatia M, Sidhapuriwala JN, Sparatore A, Moore PK (2008) Treatment with
H2S-releasing diclofenac protects mice against acute pancreatitis associated lung
injury. Shock 29: 84–88.
25. Sidhapuriwala J, Li L, Sparatore A, Bhatia M, Moore PK (2007) Effect of S-
diclofenac, a novel hydrogen sulfide releasing derivative, on carrageenan-
induced hindpaw oedema formation in the rat. Eur J Pharmacol 569: 149–
154.
26. Zhang H, Zhi l, Moochhala SM, Moore PK, Bhatia M (2007) Hydrogen sulfide
acts as an inflammatory mediator in cecal ligation and puncture induced sepsis
S-diclofenac in Doxorubicin-Induced Cardiomyopathy
PLoS ONE | www.plosone.org 12 October 2011 | Volume 6 | Issue 10 | e26441in mice by up-regulating the production of cytokines and chemokines via NF-kB.
Am J Physiol Lung Cell Mol Physiol 292: L960–L971.
27. Bhatia M, Wong FL, Fu D, Law HY, Moochhala SM, et al. (2005) Role of
hydrogen sulfide in acute pancreatitis and associated lung injury. FASEB J 19:
623–625.
28. Ling L, Bhatia M, Yizhun Z, Yichun Z, Raina DR, et al. (2005) Hydrogen
sulfide is a novel mediator of endotoxic shock. FASEB J 19: 1196–1198.
29. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, et al. (2006)
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflam-
mation. FASEB J 20: 2118–2120.
30. Fiorucci S, Antonelli E, Distrutti E, Rizzo G, Mencarelli A, et al. (2005)
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by
anti-inflammatory nonsteroidal drugs. Gastroenterology 129: 1210–1224.
31. Zhao W, Zhang J, Lu Y, Wang R (2001) The vasorelaxant effect of H2Sa sa
novel endogenous gaseous KATP channel opener. EMBO J 20: 6008–6016.
32. Bass SE, Sienkiewicz P, Macdonald CJ, Cheng RY, Sparatore A, et al. (2009)
Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human
hepatoma HepG2 and colon LS180 cells. Clin Cancer Res 15: 1964–1972.
33. Labarca C, Paigen K (1980) A simple, rapid, and sensitive DNA assay
procedure. Anal Biochem 102: 344–352.
34. Saffitz JE, Green KG, Kraft WJ, Schechtman KB, Yamada KA (2000) Effects of
diminished expression of connexin43 on gap junction number and size in
ventricular myocardium. Am J Physiol Heart Circ Physiol 278: H1662–H1670.
35. Luke RA, Saffitz JE (1991) Remodeling of ventricular conduction pathways in
healed canine infarct border zones. J Clin Invest 87: 1594–1602.
S-diclofenac in Doxorubicin-Induced Cardiomyopathy
PLoS ONE | www.plosone.org 13 October 2011 | Volume 6 | Issue 10 | e26441